Nearly 7 million Americans have been diagnosed with dementia, which slowly erodes memory, thinking skills and the ability to ...
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...
A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...
The world’s largest study of proteins circulating the human body will begin in the UK this month, with the aim of pinpointing ...
Summary: A new study has identified a biomarker, DTI-ALPS, which connects glymphatic system dysfunction to vascular dementia.
A study from the Keck School of Medicine of USC has tested a biomarker linked to vascular dementia across four separate ...
The first pill to slow down the progression of Alzheimer’s disease is being studied for use on the NHS ...
Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...
Dementia drivers license loophole sparks safety concerns in South Korea Koreas lack of legal measures puts dementia patients ...
With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback